Botulism Clinical Trial
Official title:
A Phase I, Blinded, Placebo-controlled, Dose-escalation Study of the Safety and Pharmacokinetics of XOMA 3AB Administered Intravenously in Healthy Adults
This is a phase I, single-center, placebo-controlled, double-blinded, dose escalation study of anti-botulinum toxin monoclonal antibodies in healthy adult volunteers. Volunteers will be hospitalized in the Johns Hopkins Phase 1 unit during the infusion and until after the 24-hour blood draw. Three escalating dose cohorts of a combination of three anti-botulinum monoclonal antibodies will be evaluated. Each cohort will consist of eight volunteers in which they will receive a single intravenous infusion of active drug or placebo. Placebo will be normal saline. Volunteers will be followed for safety for up to 120 days after infusion depending on dose cohort.
This is a phase I, single-center, placebo-controlled, double-blinded, dose escalation study of anti-botulinum toxin monoclonal antibodies in healthy adult volunteers. Volunteers will be hospitalized in the Johns Hopkins Phase 1 unit during the infusion and until after the 24-hour blood draw. Three escalating dose cohorts of a combination of three anti-botulinum monoclonal antibodies will be evaluated. Each cohort will consist of eight volunteers in which they will receive a single intravenous infusion of active drug or placebo. Placebo will be normal saline. Volunteers will be followed for safety for up to 120 days after infusion depending on dose cohort. ;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03603665 -
A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults
|
Phase 1 | |
| Not yet recruiting |
NCT04550793 -
Using Shear Wave Ultrasound Elastography for Follow up After Anti-spastic Intervention Among Stroke Patients
|
||
| Completed |
NCT01441557 -
Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05769478 -
Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA
|
Phase 1 | |
| Withdrawn |
NCT01940315 -
Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B
|
Phase 3 | |
| Enrolling by invitation |
NCT02051062 -
BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients
|
Phase 4 | |
| Completed |
NCT02055183 -
BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin
|
||
| Completed |
NCT03676634 -
Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®
|
Phase 2 | |
| Completed |
NCT00314080 -
Treatment of Survivors After Botulism Outbreak
|
N/A | |
| Not yet recruiting |
NCT06112834 -
Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®
|
Phase 2 | |
| Completed |
NCT00348426 -
Botulism Outbreak in Thailand (Episode II)
|
Phase 4 | |
| Completed |
NCT00004401 -
Study of Human Botulism Immunoglobulin in Infants With Botulism
|
N/A | |
| Completed |
NCT01701999 -
Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid
|
Phase 2 | |
| Completed |
NCT02779140 -
Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632
|
Phase 1 |